Abstract:Due to the poor permeability across Gram-negative bacterial membranes and the troublesome bacterial efflux mechanism, only a few GyrB/ParE inhibitors with potent activity against Gram-negative pathogens have been reported. Among them, pyrimido[4,5-b]indole derivatives represented by GP-1 demonstrated excellent broad-spectrum antibacterial activity against both Gram-positive and Gram-negative bacteria but were limited by hERG inhibition and poor pharmacokinetics profile. To improve their drug-like properties, we designed a series of novel pyrimido[4,5-b]indole derivatives based on the tricyclic scaffold of GP-1 and the C-7 moiety of acorafloxacin. These efforts have culminated in the discovery of a promising compound 18r with reduced hERG liability and an improved PK profile. Compound 18r exhibited superior broad-spectrum in vitro antibacterial activity compared to GP-1, including a variety of clinical multidrug G– pathogens, especially Acinetobacter baumannii, and the in vivo efficacy was also demonstrated in a neutropenic mouse thigh model of infection with multidrug-resistant A. baumannii.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00621?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00621</a>.More MIC data and details of tested compounds for <a class="ref showTableEvent internalNav" href="#tbl1">Tables </a><a class="ref showTableEvent internalNav" href="#tbl1">1</a>, <a class="ref showTableEvent internalNav" href="#tbl3">3</a>, and <a class="ref showTableEvent internalNav" href="#tbl4">4</a>; more MIC data and details of tested compounds for <a class="ref showTableEvent internalNav" href="#tbl5">Table </a><a class="ref showTableEvent internalNav" href="#tbl5">5</a>; metabolite identification of compound 18k in rat liver microsomes; proposed metabolic pathways of compound 18k; preparation and characterization data of all intermediates; NMR spectra and HRMS data of final compounds; and HPLC traces for lead compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00621/suppl_file/jm1c00621_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00621/suppl_file/jm1c00621_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes

In vitro Effect of the Combination of Aztreonam and Amoxicillin/Clavulanic Acid Against Carbapenem-Resistant Gram-Negative Organisms Producing Metallo--Lactamase

Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases

ETX2514 is a Broad-Spectrum Β-Lactamase Inhibitor for the Treatment of Drug-Resistant Gram-negative Bacteria Including Acinetobacter Baumannii

Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases

Discovery of an antivirulence compound that reverses β-lactam resistance in MRSA

Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens

In Vitro Activity of the Novel -Lactamase Inhibitor Taniborbactam (VNRX-5133), in Combination with Cefepime or Meropenem, Against MDR Gram-negative Bacterial Isolates from China

Lacticaseibacillus rhamnosus CRL 2244 secreted metabolites display killing and antibiotic synergistic activity against multi-drug resistant pathogens

Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5- b ]indole Derivatives Against Gram-Negative Multidrug-Resistant Pathogens

Optimization of Ethoxzolamide Analogs with Improved Pharmacokinetic Properties for In Vivo Efficacy against Neisseria gonorrhoeae

An engineered prodrug selectively suppresses β-lactam resistant bacteria in a mixed microbial setting

A new class of synthetic retinoid antibiotics effective against bacterial persisters

Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria

In Vitro Activity Of The Novel Beta-Lactamase Inhibitor Taniborbactam (Vnrx-5133), In Combination With Cefepime Or Meropenem, Against Mdr Gram-Negative Bacterial Isolates From China

Practical Application of Aztreonam-Avibactam as a Treatment Strategy for Ambler Class B Metallo-β-Lactamase Producing Enterobacteriaceae

Triple-acting Lytic Enzyme Treatment of Drug-Resistant and Intracellular Staphylococcus aureus

Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104)

Design, synthesis, and bioactivity investigation of novel cyclic lipopeptide antibiotics targeting top-priority multidrug-resistant gram-negative bacteria

A novel antibiotic class targeting the lipopolysaccharide transporter

Restoring susceptibility to β-lactam antibiotics in methicillin-resistant Staphylococcus aureus